Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors

The histone methyltransferase Enhancer of Zeste Homolog 2 (EZH2) is frequently dysregulated in cancers, and gain-of-function (GOF) EZH2 mutations have been identified in non-Hodgkin lymphomas. Small-molecule inhibitors against EZH2 demonstrated anti-tumor activity in EZH2-mutated lymphomas and enter...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibaja, V, Shen, F, Harari, J, Korn, J, Ruddy, D, Saenz-Vash, V, Zhai, H, Rejtar, T, Paris, C G, Yu, Z, Lira, M, King, D, Qi, W, Keen, N, Hassan, A Q, Chan, H M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744243/
https://www.ncbi.nlm.nih.gov/pubmed/25893294
http://dx.doi.org/10.1038/onc.2015.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744243/
https://www.ncbi.nlm.nih.gov/pubmed/25893294
http://dx.doi.org/10.1038/onc.2015.114

Ejemplares similares